Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Safety of TTYP01 Tablets to Radicava Injection and Radicava ORS in Healthy Subjects
NCT06107205Phase 1Completed
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FAB122 in amyotrophic lateral sclerosis (ALS) (3 arms). Primary endpoints: Area under the plasma concentration-time curve from time 0 extrapolated to infinity, Area under the plasma concentration-time curve from time 0 to the last measurable non-zero concentration and 1 more. Started Nov 2023; status: completed.
02
Drugs
FAB122
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06107205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107205.